BJMO - volume 12, issue 8, december 2018
B. Van den Heuvel MD, M. Rasschaert MD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD
Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.
Read moreBJMO - volume 12, issue 8, december 2018
T. Vermassen PhD, S. Rottey MD, PhD
From the 19th till the 23rd of September, Munich was host for the 2018 ESMO Congress. The central theme of the congress was ‘Securing access to optimal cancer care’. This year’s venue was attended by more than 25,000 registered attendees. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.
Read moreBJMO - volume 12, issue 8, december 2018
L. Polastro , J. Kerger MD
During this year’s ESMO Congress in Munich, which was attended by over 28,000 participants, the vast majority of presentations and communications in the gynaecological cancer domain were devoted or restricted to ovarian cancer. This included at least one major breakthrough and practice-changing study in the first-line treatment of BRCA mutated high grade serous and endometrioid ovarian cancer.
Read moreBJMO - volume 12, issue 8, december 2018
Tom Feys MBA, MSc
The introduction of immune checkpoint inhibitors and the combined use of BRAF and MEK inhibitors dramatically changed the treatment landscape of advanced melanoma over the last decade. The success of these agents in the advanced setting formed the basis to also evaluate these drugs in less advanced disease stages. During ESMO 2018 updates were given on the adjuvant use of dabrafenib and trametinib in resected stage III melanoma patients. In addition to this, results were presented on the use of immune checkpoint inhibitors in the neo-adjuvant setting. In the advanced melanoma setting, the most important data came from the four-year survival update of the CheckMate 067 trial and the presentation of the Keynote-022 study, in which the immune checkpoint inhibitor pembrolizumab was used in combination with dabrafenib and trametinib in the first-line treatment of BRAF-mutation positive advanced melanoma.
Read moreBJMO - volume 12, issue 7, november 2018
H. Van Poppel MD, PhD
At the occasion of the Annual Congress of the European Association of Urology (EAU), a number of new trial protocols with new immuno-oncology drugs were presented for bladder and renal cancer next to the results of studies on adjuvant and neo-adjuvant chemotherapy for upper tract transitional cell carcinoma. In prostate cancer, the value of prostate-specific antigen screening and multiparametric MRI at first diagnosis was investigated, and the results of clinical trials with enzalutamide and apalutamide were reported.
(BELG J MED ONCOL 2018;12(7):339–341)
Read moreBJMO - volume 12, issue 5, september 2018
W. Lybaert MD, T. Vandamme MD, PhD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD
March 7-9, 2018, Barcelona, Spain.
(BELG J MED ONCOL 2018:12(5):252–262)
Read moreBJMO - volume 12, issue 4, august 2018
J. Vansteenkiste MD, PhD, C. Dooms MD, PhD
This article will briefly discuss the top stories in the field of respiratory oncology presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO). For a complete overview of abstracts we refer to the official meeting website: https://am.asco.org.
Read more
Top
